Concept
Etcamah Approval
10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE / 1. Etcamah for ESR1-Mutated Breast Cancer
"Etcamah (camizestrant), taken with a CDK4/6 inhibitor, is for HR-positive, HER2-negative advanced breast cancer when a blood test finds an ESR1 mutation during first-line treatment, before scans show growth. In the SERENA-6 trial, people who switched went a median of 16 months before their cancer progressed, vs 9.2 months for those who didn't. CURE first covered the trial when results showed the switch delayed progression."
Related Ideas
- Treatment Findings10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Treatment Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Treatment Combination10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Breast Cancer10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · References:
- Imlunestrant Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · References:
- September Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Immune ResponseFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Dynamic CtdnaFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance